Nyxoah S.A.

NYXH • Medical - Specialties

$0.94

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$40.62M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 64.6%Nivel de deuda manejable · 0.86Rentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 12 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.94

Change0.00%

Shares Out43.21M

Market Cap$40.62M

52W Range1.26 - 8.59

Beta0.62

P/E-0.89

P/S8.88

P/B1.81

P/FCF-2.92

EV/Sales17.98

EV/EBITDA-6.09

Price$0.94

Change0.00%

Shares Out43.21M

Market Cap$40.62M

52W Range1.26 - 8.59

Beta0.62

P/E-0.89

P/S8.88

P/B1.81

P/FCF-2.92

EV/Sales17.98

EV/EBITDA-6.09

EV/FCF-5.92

Earnings Yield-28.19%

FCF Yield-34.22%

Dividend Yield0.00%

Gross Margin63.13%

Oper. Margin-8.28%

Profit Margin-8.99%

Debt/Eq0.86

Current Ratio1.25

Quick Ratio1.16

Target$4.08

Target Upside334.04%

Target Median$3.50

Target Range2.31 - 7.00

Volume100.53K

Avg Volume256.13K

EPS Surprise0.11

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

59/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

49/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 64.6%Nivel de deuda manejable · 0.86Rentabilidad débil

Analyst view

Analyst sentiment and price target

NYXH

Analyst sentiment

Based on 5 analyst votes · 2026-10-20

90/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-24

Bajo

$3.00

Promedio

$5.00

Mediana

$5.00

Alto

$7.00

Resumen de la compañía

IPO: 4/28/2021

Industria: Medical - Specialties

P/B i: 1.81

Deuda / Patrimonio i: 0.86

Margen operativo: -827.76%

Margen neto: -899.05%

ROE i: -

ROIC: -

Salud financiera

Puntaje12 / 20

Deuda / Patrimonio: 0.86

Ratio corriente: 1.25

Ratio rápido: 1.16

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Nyxoah S.A.

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Fuente - Link

Competidores

CATX GNFT IVVD KRMD OABI OSUR PRE STIM TARA UTMD

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher

Nyxoah (NYXH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third quarter global preliminary net revenue of €9.2 million PMA supplement submitted to the FDA to expand Genio's U.S. indication to Complete Concentric Collapse patients Mont-Saint-Guibert, Belgium – October 19, 2026, 2:00 pm CET / 08:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited third quarter 2026 financial and operating results and adjusted revenue guidance for 2026. Third Quarter 2026 – Preliminary Sales and Market Metrics Financials Global net revenue is expected to be approximately €9.2 million in the third quarter of 2026, which reflects 19% sequential growth over the second quarter of 2026 U.S. net revenue is expected to be approximately €6.7 million in the third quarter of 2026, which reflects 29% sequential growth over the second quarter of 2026 Leading U.S. commercial indicators 80 new surgeons trained in Q3, bringing the total to 342 surgeons trained 53 new accounts activated in Q3, bringing the total to 233 active high-volume accounts 447 patients actively under prior authorization entering Q4 Clinical and Regulatory ACCCESS U.S. pivotal study met its co-primary efficacy endpoints and its safety endpoints in Complete Concentric Collapse (CCC) patients, with a 12-month AHI responder rate of 77.2% (p

GlobeNewsWire

Contrasting Nephros (NASDAQ:NEPH) & Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ: NYXH - Get Free Report) and Nephros (NASDAQ: NEPH - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends. Profitability This table compares Nyxoah and Nephros' net margins,

Defense World

Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.

Nyxoah is entering its first growth stage, targeting the OSA device market with the Genio implant, and is currently undervalued relative to growth prospects. Genio could secure a monopoly on 30% of the OSA market by 2027, pending FDA label extension for Complete Concentric Collapse (CCC) patients, supported by strong clinical trial results. NYXH projects €36 million revenue for 2026, up 260% YoY, with visibility supported by rapid growth in trained surgeons, active accounts, and prior authorizations.

Seeking Alpha

Nyxoah Appoints Liam Kelly as Chief Executive Officer

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company's strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. The appointment reflects Nyxoah's continued evolution into a U.S.-focused commercial organization following FDA approval and the launch of Genio in the United States.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-12	-0.54	-0.43	0.11
2026-03-19	-0.65	-0.68	-0.03
2025-11-13	-0.61	-0.74	-0.13
2025-08-18	-0.62	-0.63	-0.01
2025-05-14	-0.49	-0.63	-0.14
2025-03-13	-0.46	-0.49	-0.03
2024-11-06	-0.46	-0.55	-0.09
2024-08-06	-0.45	-0.46	-0.01
2024-05-14	-0.45	-0.45	0
2024-03-05	-0.41	-0.41	0
2023-11-08	-0.48	-0.29	0.19
2023-08-08	-0.45	-0.49	-0.04